Boyd MA - Search Results

1

Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.

Autar RS, Boyd MA, Wit FW, Ruxrungthams K, Sankote J, Lange J, Cooper DA, Phanuphak P, Burger DM, Reiss P. Autar RS, et al. Among authors: boyd ma. Antivir Ther. 2007;12(8):1265-71. Antivir Ther. 2007. PMID: 18240866

2

Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects.

Boyd MA, Aarnoutse RE, Ruxrungtham K, Stek M Jr, van Heeswijk RP, Lange JM, Cooper DA, Phanuphak P, Burger DM. Boyd MA, et al. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):134-9. doi: 10.1097/00126334-200310010-00003. J Acquir Immune Defic Syndr. 2003. PMID: 14526202

3

The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.

Boyd MA, Siangphoe U, Ruxrungtham K, Reiss P, Mahanontharit A, Lange JM, Phanuphak P, Cooper DA, Burger DM. Boyd MA, et al. J Antimicrob Chemother. 2006 Jun;57(6):1161-7. doi: 10.1093/jac/dkl112. Epub 2006 Apr 4. J Antimicrob Chemother. 2006. PMID: 16595641

4

Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).

Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M Jr, Lange J, Cooper DA, Phanuphak P. Boyd MA, et al. Antivir Ther. 2006;11(2):223-32. Antivir Ther. 2006. PMID: 16640103 Clinical Trial.

5

Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz.

Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P. Boyd MA, et al. J Infect Dis. 2006 Sep 1;194(5):642-50. doi: 10.1086/505709. Epub 2006 Jul 18. J Infect Dis. 2006. PMID: 16897663

6

Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.

Yao AH, Moore CL, Lim PL, Molina JM, Madero JS, Kerr S, Mallon PW, Emery S, Cooper DA, Boyd MA; SECOND-LINE study group. Yao AH, et al. Among authors: boyd ma. Antivir Ther. 2018;23(1):21-32. doi: 10.3851/IMP3171. Antivir Ther. 2018. PMID: 28447585

7

Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.

Boyd MA, Siangphoe U, Ruxrungtham K, Duncombe CJ, Stek M, Lange JM, Cooper DA, Phanuphak P. Boyd MA, et al. HIV Med. 2005 Nov;6(6):410-20. doi: 10.1111/j.1468-1293.2005.00327.x. HIV Med. 2005. PMID: 16268823 Free article. Clinical Trial.

8

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.

Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA. Law WP, et al. Among authors: boyd ma. AIDS. 2003 Oct 17;17(15):2191-9. doi: 10.1097/00002030-200310170-00007. AIDS. 2003. PMID: 14523276

9

Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.

Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA, Dore GJ. Law WP, et al. Among authors: boyd ma. AIDS. 2004 May 21;18(8):1169-77. doi: 10.1097/00002030-200405210-00010. AIDS. 2004. PMID: 15166532 Clinical Trial.

10

Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.

Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO. Boyd MA, et al. Pharmacogenet Genomics. 2006 May;16(5):321-9. doi: 10.1097/01.fpc.0000197465.14340.d4. Pharmacogenet Genomics. 2006. PMID: 16609363

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

221 results

Search Page

Filters